Q-linea ABFRA:3F80 +1.00%68 Days Payable is 413.59 as of Mar. 2026, which is 206% above its 10-year median of 134.96. GuruFocus rates FRA:3F80 with a GF Score™ of 68/100 and a GF Value™ of kr1.86. The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Q-linea AB ranks better than 80.63% on this metric.
Q-linea AB's average Accounts Payable for the
three
months ended in Mar. 2026 was kr5.78 Mil. Q-linea AB's Cost of Goods Sold for the
three
months ended in Mar. 2026 was kr1.28 Mil.
Hence, Q-linea AB's Days Payable for the
three
months ended in Mar. 2026 was 413.59.
The historical rank and industry rank for Q-linea AB's Days Payable or its related term are showing as below:
FRA:3F80'
s Days Payable Range Over the Past 10 Years
Min: 85.88 Med: 134.96 Max: 1422.92
Current: 169.07
During the past 11 years, Q-linea AB's highest Days Payable was 1422.92. The lowest was 85.88. And the median was 134.96.
FRA:3F80's Days Payable is ranked better than 80.63% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs FRA:3F80: 169.07
Q-linea AB's Days Payable
increased
from Mar. 2025 (141.18) to Mar. 2026 (413.59).
It may suggest that Q-linea ABdelayed paying its suppliers.
Q-linea AB Days Payable Related Terms
Q-linea AB Days Payable Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3F80 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Q-linea AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Q-linea AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (FRA:3F80) has a Days Payable of 413.59 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Q-linea AB and its competitors. This is 206% above median its historical median of 134.96. Over the past decade, Q-linea AB's Days Payable has ranged from 85.88 to 1,422.92. According to the industry distribution chart, Q-linea AB ranks #154 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 19.4%.
Is Q-linea AB's Days Payable too high?
Q-linea AB's current Days Payable of 413.59 is 206% above median its 10-year median of 134.96. Over the past 10 years, this metric has ranged from a low of 85.88 to a high of 1,422.92. The Medical Devices & Instruments industry median Days Payable is 68.07. Q-linea AB's value of 413.59 is 507.6% above this industry median. Based on the distribution chart, Q-linea AB ranks #154 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-linea AB has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #154 out of 795 companies for Days Payable. This places Q-linea AB in the top 19% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Q-linea AB's value of 413.59 is 507.6% above this benchmark. Historically, Q-linea AB's own Days Payable has ranged from 85.88 to 1,422.92 over the past decade. While the company's 10-year median is 134.96 vs. the industry median of 68.07, Q-linea AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current Days Payable of 413.59 is 507.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current Days Payable is 413.59, which is 206% above median its own 10-year median of 134.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (FRA:3F80) has a current Days Payable of 413.59. The stock's GF Value™ is kr1.86, compared to a current price of kr1.52 — trading 18.5% below its estimated fair value. The current Days Payable is 413.59, which is 206% above median its 10-year median of 134.96 and 507.6% above the Medical Devices & Instruments industry median of 68.07. Q-linea AB's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Q-linea AB (FRA:3F80), the current Days Payable is 413.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (FRA:3F80) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1.52 is trading 18.5% below its estimated GF Value™ of kr1.86.
Key valuation signals for FRA:3F80:
Days Payable: 413.59 (206% above median its 10-year median of 134.96)
GF Value™: kr1.86 vs. price of kr1.52 (18.5% below fair value)
Industry Position: 507.6% above the Medical Devices & Instruments median (#154 of 795)
No single metric tells the full story. See the FRA:3F80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
68GF Score
Get the complete analysis for FRA:3F80
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3F80 has been successfully added to your 
